Growth Equity

A modest SEK 1.5 million order may not turn heads, but for Cell Impact, it's a critical validation that could unlock mass production in the booming Asian FCEV market.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

Amidst a nuclear renaissance, Global Uranium’s detailed mapping in Wyoming de-risks a key project, setting the stage for a critical 2026 drill program.

Beyond insurance, Sammons Financial Group is building a holistic financial services model. What does this strategic pivot mean for clients and the industry?

As the humanoid robotics market soars towards $7.7B, one firm is recruiting top talent to find the next big winner. What does this move signal to investors?

A sleepy cat GIF with 2.4B views is now a children's book. We analyze the business strategy behind turning viral fame into a publishing success story.

Advanced aerial surveys reveal massive, untapped deposits of copper and nickel in Canada's far north, potentially rivaling the world's largest mineral reserves.

With a fresh $62M in funding, WELLSTAR is accelerating its AI and acquisition strategy ahead of a planned 2026 spinout, aiming to rewire Canadian healthcare.

A landmark government scheme is injecting billions into innovation. Can venture capitalists like Beyond Ventures turn this capital into a tech and health boom?

Intensity Therapeutics has a promising cancer therapy in late-stage trials, but can its scientific innovation outpace a looming Nasdaq delisting threat?

A PE firm's strategic leadership expansion signals a major push to scale capital and master the dual worlds of sustainable and conventional energy investment.

SkinSpirit's new Princeton clinic isn't just an expansion; it's a strategic move in the booming medical aesthetics market. Here's why it matters.